The report “Interventional Cardiology & Peripheral Vascular Devices Market (Embolic Protection, Chronic Total Occlusion, Atherectomy, Thrombectomy, IVUS, Angiography Catheters, EVAR Stent Grafts, IVC Filters, Stents, Balloons and Accessories) - Forecasts to 2019”, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the interventional cardiology and peripheral vascular devices market along with the estimates and forecasts of the revenue and market share analysis.

Browse 152 market data tables and 50 figures spread through 163 pages and in-depth TOC on “Interventional Cardiology & Peripheral Vascular Devices Market

http://www.marketsandmarkets.com/Market-Reports/minimally-invasive-interventional-cardiology-devices-market-548.html
Early buyers will receive 10% customization on reports.

Key players in this market include Abbott Laboratories (U.S.), Boston Scientific (U.S.), B. Braun Melsungen AG (Germany), Cordis Corporation (U.S.), C.R. Bard, Inc. (U.S.), Medtronic Inc. (U.S.), Terumo Corporation (Japan), and Volcano Corporation (U.S.).

Download PDF brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=548

Based on geography, the global interventional cardiology and peripheral vascular devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this geographic segment is driven by factors such as rising incidence of cardiovascular diseases, rising aging population base, and technological advancements.

Request sample of this report@ http://www.marketsandmarkets.com/requestsample.asp?id=548

The report segments this market based on products that include angioplasty balloons, angioplasty stents, catheters, EVAR stent grafts, IVC filters, plaque modification devices, hemodynamic flow alteration devices, and accessories. Among various products, the angioplasty stents segment is expected to account for the largest share of the market. High growth in this segment can be attributed to the increasing company investments to develop new stents with better clinical outcomes.